Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

Date Added
July 29th, 2019
PRO Number
Pro00090904
Researcher
Amarendra Neppalli

List of Studies


Keywords
Cancer, Cancer/Myeloma
Summary

This study is for patients that have been diagnosed with smoldering multiple myeloma (SMM). The drugs used in this study are daratumumab, lenalidomide and dexamethasone which are all commercially used drugs. The purpose of this study is to compare overall survival in patients with high-risk smoldering multiple myeloma randomized to daratumumab revlimid-dexamethasone or revlimid-dexamethasone. Participants can expect to be on this study for up to two years and followed by your doctor for up to 15 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu



-- OR --